Neuromyelitis Optica Spectrum Disorders (NMOSD)
·MeSH: Neuromyelitis Optica
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| Eculizumab administration | Valneva SE (VALN) |
Frequently asked questions
How many drugs are in development for Neuromyelitis Optica Spectrum Disorders (NMOSD)?
BioSniper tracks 1 drug in development for Neuromyelitis Optica Spectrum Disorders (NMOSD) across 1 company.
How many clinical trials target Neuromyelitis Optica Spectrum Disorders (NMOSD)?
There are 1 clinical trial targeting Neuromyelitis Optica Spectrum Disorders (NMOSD) tracked by BioSniper.
What is the prevalence of Neuromyelitis Optica Spectrum Disorders (NMOSD)?
The estimated prevalence of Neuromyelitis Optica Spectrum Disorders (NMOSD) is approximately 30.0 per 100,000 population.
Deep-dive into Neuromyelitis Optica Spectrum Disorders (NMOSD)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis